Spinal muscular atrophy (SMA) is a rare, genetic and progressive neuromuscular disorder characterized by weakness of the skeletal and respiratory muscles. SMA is caused by a missing gene that encodes the survival motor neuron (SMN) protein. The SMN protein is critical to the health and survival of the nerve cells in the spinal cord responsible for muscle contraction (motor neurons).

Approximately 10,000 people in the United States have SMA, which occurs in nearly 1 in 11,000 infants and is the number one genetic cause of infant death. The disease can affect any race, age or gender.

About our Patient Care

Our dedicated Care Team will work with the physician's office and insurance on a patient's behalf so that our patients have more time to focus on their treatment and quality of life. We are here to listen, provide

counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

As part of treatment, we provide:

Dedicated Care Team

We provide prescribers and patients with a dedicated care team for each of our disease state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax and email address.

Shipping and Coordination of Care

We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.

Insurance and Financial Assistance

We coordinate between the health insurance provider and patient/caregiver to ensure the prescribed therapy is approved. We work with site-of care facilities and other funding entities to help facilitate obtaining approval for the prescribed therapy.

24/7/365 Access to a Pharmacist

We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.


Subscribe to Receive Specialty Pharmacy Insights


Supported Treatments

Zolgensma (onasemnogene abeparvovec-xioi)

Brand Name | Zolgensma

Manufacturer | AveXis

Route of Administration | Intravenous (IV) infusion

Approved Indication | Treatment of pediatric patients less than 2 years of age with SMA

Self-Administration | No

Product Website | www.zolgensma.com

Partnering with Prescribers

Licensed prescribers can submit a completed enrollment form directly to our Admission team. We will begin the process and communicate with your office every step of the way.

GET STARTED

Send Us A Script